Bispecific Antibody (bsAb): A Promising Immunotherapeutic agent

 
 
LAP Lambert Academic Publishing
  • erschienen am 13. Januar 2018
 
  • Buch
  • |
  • Softcover
  • |
  • 184 Seiten
978-620-2-19818-9 (ISBN)
 
Immunotherapy as a therapeutic option for cancer therapy has contributed immensely to the success gained so far in the fight against cancer. Notwithstanding, the use of immunotherapy is not a common practice in most health facilities that handle cancer cases, and can be attributed to the fact that these immunotherapeutic agents are usually expensive compared to alternative options. This book therefore discusses the possible formats used in developing immunotherapeutic agents. Introduction and the first three chapters introduce the reader to the general concept of cancer and the various forms of cancer. The common therapeutic options and their respective therapeutic agents are also covered under these chapters. This is necessary to equip novices with basic knowledge about cancer and bring them to an appreciable level of understanding with respect to the concept of immunotherapy. Chapter four explains the various formats for developing immunotherapeutic agents as well as applications of these agents. This book will diffuse the perception that developing immunotherapeutic agent is a herculean task if not impossible, and also whip up your interest immunotherapy.
  • Englisch
  • Höhe: 220 mm
  • |
  • Breite: 150 mm
  • |
  • Dicke: 11 mm
  • 290 gr
978-620-2-19818-9 (9786202198189)
6202198184 (6202198184)
Dr. Desmond Omane Acheampong is a Senior Lecturer and Head of the Department of Biomedical Sciences, University of Cape Coast. He holds a PhD in Microbiological and Biochemical Pharmacy and MSc in Clinical Microbiology. Desmond has published extensively on Cancer Immunotherapy, and has to his credit a Patent (CN104592395A) for anti-cancer agent.

Sofort lieferbar

64,90 €
inkl. 7% MwSt.
in den Warenkorb

Abholung vor Ort? Sehr gerne!
Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok